Athens-listed Lavipharm sells Hitex SAS

Athens-listed company Lavipharm announced on Tuesday that France’s Laboratoires Lavipharm SA, in which the Greek company holds a 45 percent stake, sold and transferred Hitex SAS, a 100 percent subsidiary, to French companies Fiag Holding, Codif Recherche & Nature and Robertet for 3,127,000 euros on Monday.

This transaction is expected to have a favorable impact on Lavipharm’s financial results up to December 31, 2013.

Hitex is active in the domain of research and development in supercritical fluid technologies.